ライフサイエンスコーパス: C-reactive protein

1 f inflammation (alpha-1-acid glycoprotein or C-reactive protein).

2 tryptophan and disease activity or levels of C-reactive protein.

3 els in plasma from patients with high plasma C-reactive protein.

4 ond traditional CV risk and high-sensitivity C-reactive protein.

5 assess concentrations of hemoglobin A1c and C-reactive protein.

6 e score, anemia, hypoalbuminemia, and higher C-reactive protein.

7 diabetes, hypertension, apolipoproteins, or C-reactive protein.

8 ity cardiac troponin T, and high-sensitivity C-reactive protein.

9 ol consumption, physical activity level, and C-reactive protein.

10 ygdalar activity, arterial inflammation, and C-reactive protein.

11 found with leptin receptor, adiponectin, or C-reactive protein.

12 along with increases in cytokine levels and C-reactive protein.

13 triglycerides, HDL cholesterol (HDL-C), and C-reactive protein].

14 e rate -0.00194 (95% CI -0.00317--0.000705), C-reactive protein -0.0363 (95% CI 0.0601--0.0124), cyst

15 he following biomarkers: 1) high sensitivity C-reactive protein; 2) E-selectin; 3) tumor necrosis fac

16 nopathy (128/128), anaemia (79/91), elevated C-reactive protein (65/79), hypergammaglobulinaemia (63/

17 ; normal level, <55 U/L [<0.92 mukat/L]) and C-reactive protein (97.1 mg/L [924.8 nmol/L]; normal lev

18 Modest increases in concentration of C-reactive protein, a circulating marker of inflammation

19 ith adiposity, triglycerides, liver enzymes, C-reactive protein, a genetic score representing insulin

20 slightly, but remained, after adjustment for C-reactive protein, a marker of low-grade inflammation (

21 CEA together with other tumor biomarkers and C-reactive protein, a universal biomarker for infection

22 clear factor-kappaB ligand, high-sensitivity C-reactive protein, adiponectin, leptin, soluble interce

23 s of low-density lipoprotein cholesterol and C-reactive protein after surgery were lower in patients

24 The C-reactive protein/albumin ratio (CAR) has been shown to

25 nts had significantly higher serum levels of C-reactive protein, alpha1-globulin, and alpha2-globulin

26 r the curve was 0.80 (95% CI, 0.76-0.85) for C-reactive protein and 0.78 (95% CI, 0.68-0.87) for proc

27 sgow Prognostic Score (mGPS), which combines C-reactive protein and albumin.

28 Furthermore, they found that C-reactive protein and alpha-1-acid glycoprotein provide

29 dia thickness and levels of high-sensitivity C-reactive protein and asymmetric dimethylarginine).

30 Genotype-dependent effects on C-reactive protein and cholesterol efflux are supportive

31 l counts as well as peaks of serum levels of C-reactive protein and fibrinogen were noticed in the fi

32 Inflammatory markers (C-reactive protein and fibrinogen) and lifestyle factors

33 high-sensitivity C-reactive protein and GlycA were increased in psoriasis

34 ive predictors of sputum %neutrophils, while C-reactive protein and IL-6 were positive predictors of

35 ng inflammatory biomarkers (high-sensitivity C-reactive protein and IL-6) and activated monocytes (CD

36 uppression use, and markers of inflammation (C-reactive protein and inflammatory cytokines) to assess

37 luence systemic inflammation [fasting plasma C-reactive protein and interleukin-6 (IL-6) as primary e

38 ed markers of inflammation (high-sensitivity C-reactive protein and interleukin-6), and there were mo

39 wo markers of inflammation, high-sensitivity C-reactive protein and interleukin-6, when the birds wer

40 th higher interleukin 6 and high-sensitivity C-reactive protein and lower free testosterone and dehyd

41 No sex differences were seen for C-reactive protein and N-terminal pro B-type natriuretic

42 The accuracy of C-reactive protein and procalcitonin did not differ at a

43 aimed to compare the predictive abilities of C-reactive protein and procalcitonin in the occurrence o

44 C-reactive protein and procalcitonin were measured daily

45 orithm using host biomarker POCTs, including C-reactive protein and procalcitonin, has the potential

46 lized plasma tumor necrosis factor-alpha and C-reactive protein and restored mitochondrial state-3 re

47 Levels of inflammation markers C-reactive protein and serum amyloid A and quality-of-li

48 tzler activity score), inflammation markers (C-reactive protein and serum amyloid A), and quality-of-

49 hronic PTSD with biomarkers of inflammation (C-reactive protein and tumor necrosis factor alpha recep

50 his meta-analysis included studies analyzing C-reactive protein and/or procalcitonin levels at postop

51 cholesterol, triglycerides, high-sensitivity C-reactive protein, and 10-year Framingham risk score we

52 est in children with edema and with elevated C-reactive protein, and a lower increase was seen with i

53 ion to measure serum retinol, beta-carotene, C-reactive protein, and alpha1-acid glycoprotein.

54 od pressure, fasting plasma lipids, glucose, C-reactive protein, and arterial stiffness [carotid-femo

55 sex, and duration of dialysis or fibrinogen, C-reactive protein, and complement C3) confirmed that de

56 of inflammation, such as fecal calprotectin, C-reactive protein, and Crohn's disease activity index s

57 ine, patients had much higher interleukin-6, C-reactive protein, and hepcidin levels.

58 ascular disease risk score, high-sensitivity C-reactive protein, and homocysteine.

59 measurement of pathogen density, and use of C-reactive protein, and how these affect pneumonia etiol

60 erythropoietin, serum folate, vitamin B-12, C-reactive protein, and interleukin-6.

61 nsity lipoprotein cholesterol, vitamin D and C-reactive protein, and less central obesity).

62 obin, N-terminal B-type natriuretic peptide, C-reactive protein, and leukocyte count.

63 tant protein-1, tumor necrosis factor-alpha, C-reactive protein, and phospholipase A2.

64 lipoprotein cholesterol and high-sensitivity C-reactive protein, and use of nonsteroidal anti-inflamm

65 blood glucose, LDL-to-HDL cholesterol ratio, C-reactive protein, angiotensin II, and albuminuria redu

66 (neopterin, kynurenine:tryptophan ratio, and C-reactive protein), anthranilic acid, and 3-hydroxykynu

67 colchicine, and an elevated high-sensitivity C-reactive protein are associated with the development o

68 m uric acid, serum albumin, albuminuria, and C reactive protein as non-GFR determinants of eGFRcys.

69 te-macrophage colony-stimulating factor, and C-reactive protein at enrollment as well as after 7-14 d

70 , women with chronic PTSD had higher average C-reactive protein (B = 0.27, p < .05), tumor necrosis f

71 d measures of B-type natriuretic peptide and C-reactive protein before the procedures.

72 , level of glycated hemoglobin A1c, level of C-reactive protein, body mass index, and platelet count

73 in, triglycerides, type 2 diabetes mellitus, C-reactive protein, body mass index, systolic blood pres

74 ol, triglycerides, type 2 diabetes mellitus, C-reactive protein, body mass index, systolic blood pres

75 ith >/=3 previous recurrences), elevation of C-reactive protein, colchicine resistance, and corticost

76 howed a significant increase in NL levels of C-reactive protein compared to control-day exposure.

77 lin A, and pyruvate kinase), and pentameric (C-reactive protein) complexes, ranging in size up to 237

78 Biochemical risk factors were a plasma C-reactive protein concentration >15 mg/L on admission a

79 exclusion of individuals with inflammation (C-reactive protein concentration >5 mg/L or alpha-1-acid

80 ial risk factors, including high-sensitivity C-reactive protein concentration, the association betwee

81 we demonstrate the technique by quantifying C-reactive protein concentrations in human serum over a

82 In addition, controlling for baseline C-reactive protein, copper, or albumin did not change th

83 C-reactive protein correlated with urticaria activity (P

84 The relationship between mGPS [0-C-reactive protein (CRP) </= 10 mg/L, 1-CRP > 10 mg/L an

85 leukocyte cell adhesion molecule (ALCAM) and C-reactive protein (CRP) (p < 0.05), and IQR increases i

86 ta-analyses indicated that prebiotics reduce C-reactive protein (CRP) [standardized mean difference (

87 (GPx) and inflammation biomarkers, including C-reactive protein (CRP) and a panel of cytokines (inter

88 stigated whether circulating levels of serum C-reactive protein (CRP) and a weighted genetic CRP scor

89 Effects of C-reactive protein (CRP) and alpha1-acid glycoprotein (A

90 inequalities in inflammation -assessed using C-reactive protein (CRP) and fibrinogen- varied across t

91 ar risk factors (cholesterol, high-sensitive C-reactive protein (CRP) and HbA1c).

92 White blood count (WBC), C-reactive protein (CRP) and PCT levels were measured in

93 this study was to evaluate the expression of C-reactive protein (CRP) and serum amyloid A (SAA), the

94 C-reactive protein (CRP) and serum amyloid P component (

95 ciations with the plasma inflammation marker C-reactive protein (CRP) and the urinary oxidative stres

96 high sensitive, selective, fast and reusable C-reactive protein (CRP) aptasensors.

97 Modest elevations in C-reactive protein (CRP) are associated with type 2 diab

98 uble CD14 (sCD14), interleukin 6 (IL-6), and C-reactive protein (CRP) at 6 weeks and 6 months of age

99 diagnostic characteristics of the PCT assay, C-reactive protein (CRP) concentration, white blood cell

100 mg/L): 1) the exclusion of individuals with C-reactive protein (CRP) concentrations >5 mg/L or alpha

101 ff to <30 mug/L; 2) exclude individuals with C-reactive protein (CRP) concentrations >5 mg/L or alpha

102 s follows: 1) the exclusion of subjects with C-reactive protein (CRP) concentrations >5 mg/L or alpha

103 gher CMV loads (P = .005) and >2-fold higher C-reactive protein (CRP) concentrations (P < .0001).

104 C-reactive protein (CRP) concentrations rise in response

105 ease severity indices, cytokine profiles and C-reactive protein (CRP) concentrations.

106 C-reactive protein (CRP) encoded by CRP gene is a reflec

107 ogies of pneumonia has limited evaluation of C-reactive protein (CRP) for identifying bacterial pneum

108 Although plasma levels of C-reactive protein (CRP) have been shown to be associate

109 for detection of the inflammatory biomarker C-reactive protein (CRP) in human serum via a miniature

110 Levels of progesterone and C-reactive protein (CRP) in plasma were determined, as w

111 For the comparison we use the C-reactive protein (CRP) induced agglutination of identi

112 C-reactive protein (CRP) is a biomarker of the inflammat

113 C-reactive protein (CRP) is a circulating inflammatory m

114 C-reactive protein (CRP) is associated with immune, card

115 C-reactive protein (CRP) is present at sites of inflamma

116 iation in the overall group, the decrease in C-reactive protein (CRP) level was smaller in overweight

117 y in relation to increased triglycerides and C-reactive protein (CRP) levels, are of concern.

118 sess the prevalence of persistently elevated C-reactive protein (CRP) levels, based on serial measure

119 .g., IL-6, tumor necrosis factor-alpha), and C-reactive protein (CRP) levels; organ dysfunction score

120 We assessed the performance of C-reactive protein (CRP) measured with a point-of-care a

121 Baseline C-reactive protein (CRP) or cytokine levels did not pred

122 higher erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) values, haemoglobin, and leukoc

123 Increased log plasma C-reactive protein (CRP) was significantly associated wi

124 EA), bilirubin, alpha fetoprotein (AFP), and c-reactive protein (CRP) were identified and included in

125 of inflammation (for example, cytokines and C-reactive protein (CRP)) are reliably elevated in depre

126 ompassing a sample of 16 870 individuals for C-reactive protein (CRP), 15 studies including 3751 indi

127 is modification is independent of age and of C-reactive protein (CRP), a marker of inflammation.

128 Elevated levels of C-reactive protein (CRP), a sensitive marker of inflamma

129 Weight loss, performance status (PS), C-reactive protein (CRP), albumin, the nutritional risk

130 and certain micronutrient biomarkers such as C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP

131 te whether FHR-1 binds to another pentraxin, C-reactive protein (CRP), analyze the functional relevan

132 or binding protein 3 (IGFBP-3), adiponectin, C-reactive protein (CRP), and interleukin 6 (IL-6), as w

133 C-reactive protein (CRP), Glasgow prognostic score (GPS)

134 ), lipopolysaccharide binding protein (LBP), C-reactive protein (CRP), ILT-4, C-C motif ligand 18 (PA

135 at most ES-62 was bound to a single protein, C-reactive protein (CRP), in normal human serum, display

136 Genetically elevated circulating levels of C-reactive protein (CRP), interleukin-1 receptor antagon

137 n > 50,000) were analyzed with assessment of C-reactive protein (CRP), interleukin-6 (IL-6), and tumo

138 Levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumo

139 kins (IL-6, IL-1beta, TNFalpha), circulatory C-reactive protein (CRP), serum amyloid A (SAA) and hapt

140 ed, for a woman with no prior day stressors, C-reactive protein (CRP), serum amyloid A (SAA), interce

141 ine responsiveness was associated with serum C-reactive protein (CRP), tumor necrosis factor, interle

142 he proinflammatory and procoagulant molecule C-reactive protein (CRP), which induces PMA formation in

143 ome-wide association studies (EWAS) of serum C-reactive protein (CRP), which is a sensitive marker of

144 trate that this device can be used to detect C-reactive protein (CRP)-a biomarker for neonatal sepsis

145 emonstrated through blood-based detection of C-reactive protein (CRP).

146 els of triglycerides, total cholesterol, and C-reactive protein (CRP).

147 tions of nut consumption with fasting plasma C-reactive protein (CRP, n = 4941), interleukin 6 (IL-6,

148 VD biomarkers such as S100 beta proteins and C-reactive proteins (CRP).

149 herapy by monitoring clinical conditions and C-reactive-protein (CRP) levels.

150 traits (body mass index [BMI] and levels of C-reactive protein [CRP] and leptin).

151 , and inflammation (LDH, bilirubin, D-dimer, C-reactive protein [CRP]) improved.

152 count, erythrocyte sedimentation rate [ESR], C-reactive protein [CRP]), and DNI were measured.

153 proteins (alpha-2 macroglobulin [alpha-2M], C-reactive protein [CRP], haptoglobin, and serum amyloid

154 Biomarkers of inflammation (C-reactive protein [CRP], interleukin 6, soluble interle

155 Proximal DVT alone, higher C-reactive protein, D-dimer, peak thrombin, lower Ks, sh

156 n, high-density lipoprotein cholesterol, and C-reactive protein, did not alter the results.

157 ristic, renal function, and high-sensitivity C-reactive protein, elevated TMAO levels remained indepe

158 C-reactive protein emerged from the proteomics analysis

159 C-reactive protein, erythrocyte sedimentation rate (ESR)

160 uate the inflammatory burden of the disease (C-reactive protein, fecal calprotectin) since symptoms-b

161 ildren with CM and SMA had greater values of C-reactive protein, ferritin, and hepcidin than those of

162 .43-2.35) after adjustment for risk factors, C-reactive protein, fibrin degradation product, and heat

163 omes, and its addition to a 3-BRS comprising C-reactive protein, fibrin degradation product, and heat

164 METHODS AND C-reactive protein, fibrin degradation product, heat sho

165 ased on the circulating levels of biomarkers C-reactive protein, fibrin degradation products, and hea

166 y associations adjusted for high-sensitivity C-reactive protein, fibrinogen, and intercellular adhesi

167 c mean percent increases in high-sensitivity C-reactive protein from baseline to end of trial of 18.1

168 , hs-TnI (high-sensitivity troponin I), CRP (C-reactive protein), GDF-15 (growth differentiation fact

169 loci assessed, a variant (rs2808630) of the C-reactive protein gene modified the associations for th

170 vein thrombosis, male sex, high-sensitivity C-reactive protein greater than 3.0 mg/dL, cystatin C >/

171 140 patients in the C-reactive protein group and 137 patients in the routine

172 total of 14 hospital admissions (six in the C-reactive protein group and eight in the control group)

173 as found in 267 (30%) of 877 patients in the C-reactive protein group versus 314 (36%) of 882 patient

174 14 days was 581 (64%) of 902 patients in the C-reactive protein group versus 738 (78%) of 947 patient

175 n=3231) or absence (n=2673) of inflammation (C-reactive protein >/=10 mg/l and/or albumin </=35 g/l).

176 0, hemoglobin </=10 g/dL, albumin </=25 g/L, C-reactive protein >/=25 mg/L, or CD4 <200/mm(3).

177 es/mL) nasopharyngeal/oropharyngeal load and C-reactive protein >/=40 mg/L (both P < .01) in nonconfi

178 ry severe pneumonia, oxygen saturation <92%, C-reactive protein >/=40 mg/L, and lack of antibiotic pr

179 ssignment: faecal calprotectin >/=250 mug/g, C-reactive protein >/=5mg/L, CDAI >/=150, or prednisone

180 mL or 0.70 mumol/L) and inflammation status (C-reactive protein >3.0 mug/mL or 120 nmol/L), respectiv

181 nflammatory signals, including cytokines and C-reactive protein, have been described in posttraumatic

182 nflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring

183 rotein cholesterol, coronary artery disease, C-reactive protein, HbA1c, height, obesity, smoking stat

184 pressure, body mass index, high-sensitivity C-reactive protein, hemoglobin A1c, HDL cholesterol, LDL

185 between tiredness and body mass index (BMI), C-reactive protein, high-density lipoprotein (HDL) chole

186 mptoms; lower hemoglobin and albumin; higher C-reactive protein; higher KSHV VL; elevated interleukin

187 were determined using serum high sensitivity C-reactive protein (hs-CRP) and a visual analogue scale

188 High-sensitivity C-reactive protein (hs-CRP) has been associated with cor

189 High-sensitivity C-reactive protein (hs-CRP) is independently associated

190 High-sensitivity C-reactive protein (hs-CRP), interleukin-1beta (IL-1beta

191 interleukin (IL)-1ra, IL-6, high-sensitivity C-reactive protein (hs-CRP), leptin and adiponectin) wer

192 ), family history (FH), and high-sensitivity C-reactive protein (hs-CRP).

193 rosis factor (TNF)-alpha, and high-sensitive C-reactive protein (hs-CRP); serum hs-CRP was also sampl

194 The inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) adds prognostic information o

195 lammatory markers including high-sensitivity C-reactive protein (hsCRP) and lipoprotein-associated ph

196 the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) correlate with clinical benef

197 ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) levels, and family history (F

198 , and had concentrations of high-sensitivity C-reactive protein (hsCRP) of 2 mg/L or greater.

199 estimates of the effect of high-sensitivity C-reactive protein (hsCRP) on BMD at the forearm, femora

200 the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) predict vascular risk with an

201 High-sensitivity C-reactive protein (hsCRP) was measured from serum.

202 lammatory markers GlycA and high-sensitivity C-reactive protein (hsCRP) with 24-h sodium excretion.

203 Interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP), and D-dimer levels are linke

204 clinical parameters, serum high-sensitivity C-reactive protein (hsCRP), and plasma fibrinogen.

205 d points included change in high-sensitivity C-reactive protein (hsCRP), FMDBA after acute ascorbic a

206 gic marker of inflammation (high-sensitivity C-reactive protein [hsCRP]) and insulin resistance (home

207 le markers of inflammation (high-sensitivity C-reactive protein [hsCRP]), immune activation (soluble

208 ern associated with markers of inflammation (C-reactive protein, IL6, and TNFalpha receptor 2).

209 course of the disorder, including cytokines; C-reactive protein; immune cells; antibodies, autoantibo

210 icts subclinical CVD beyond high-sensitivity C-reactive protein in psoriasis is unknown.

211 seems not to have added value as compared to C-reactive protein in this setting.

212 cale Discovery V-Plex Plus: high-sensitivity C-reactive protein, interferon-gamma, interleukin (IL)-1

213 C-reactive protein is more accurate than procalcitonin f

214 me familiar with the clinical picture of low C-reactive protein, leading to reduction in antibiotic p

215 the 28-joint Disease Activity Score based on C-reactive protein level (DAS28-CRP), and a Simplified D

216 ardless of baseline iron repletion status or C-reactive protein level and with oral or IV iron supple

217 d a white blood cell count of 6.7 x 10(9), a C-reactive protein level of 29 mg/L (276.2 nmol/L) (norm

218 ammation, and in patients with CKD, elevated C-reactive protein level predicts cardiovascular risk.

219 tation rate was elevated at 56 mm/h, and her C-reactive protein level was normal at 4.4 mg/L (41.9 nm

220 y level, erythrocyte sedimentation rate, and C-reactive protein level were normal.

221 including prevalent diabetes, hypertension, C-reactive protein level, and white blood cell count, th

222 ardiovascular risk at baseline, lipid level, C-reactive protein level, blood pressure, and race or et

223 e smoking, diabetes status, body mass index, C-reactive protein level, hemoglobin A1c level, phosphor

224 egardless of baseline iron repletion status, C-reactive protein level, iron regimen, or dialysis moda

225 ependent of and additive to high-sensitivity C-reactive protein level.

226 icular ejection fraction (<50%) and elevated C-reactive protein levels (>2 mg/L), within 14 days of h

227 B-type natriuretic peptide levels (P=0.01), C-reactive protein levels (P<0.0001), and left atrial si

228 ls correlated with low total IgE levels, low C-reactive protein levels and low prevalence of parasiti

229 d, United Kingdom), which reduced both serum C-reactive protein levels and peripheral blood monocyte

230 a lower rate of prevalent diabetes and lower C-reactive protein levels and white blood cell counts.

231 ts had significantly higher highly sensitive-C-reactive protein levels compared to Controls (2.1 +/-

232 insulin, HbA1c, leptin, and high-sensitivity C-reactive protein levels from fasting samples using mul

233 C-reactive protein levels have proved to be accurate in

234 ith controls, cases had significantly higher C-reactive protein levels in the discovery, replication,

235 levels less than 130 mg/dL, high-sensitivity C-reactive protein levels of at least 2 mg/L, and trigly

236 ns of inflammation, their serum cytokine and C-reactive protein levels typically are elevated.

237 A significant 30% decrease in C-reactive protein levels was observed among women rando

238 dy mass index, CD4 cell count, HIV load, and C-reactive protein levels were analyzed.

239 C-reactive protein levels were significantly higher in n

240 in those with nonmelioidosis sepsis, whereas C-reactive protein levels were similar in both groups.

241 smoking and inflammatory biomarkers (IL6 and C-reactive protein levels).

242 analyses, B-type natriuretic peptide levels, C-reactive protein levels, and left atrial size were ass

243 , phosphorus, intact parathyroid hormone, or C-reactive protein levels, cinacalcet use, or phosphate

244 ers, BAT results, complete blood cell count, C-reactive protein levels, thyroid-stimulating hormone l

245 bles the rapid and precise quantification of C-Reactive protein levels, within the clinically relevan

246 for blood pressure, blood lipid levels, and C-reactive protein levels.

247 t loss strategies, with favorable effects on C-reactive protein levels.

248 creased adiponectin levels without change in C-reactive protein levels.

249 ensity lipoprotein cholesterol but increased C-reactive protein levels.

250 metabolic profiles, hs-CRP (high-sensitivity C-reactive protein) levels, oxidative stress markers (gl

251 lar function, and metabolism (high-sensitive C-reactive protein, lipids, fibrinogen, oxidative stress

252 e; gamma-glutamyltransferase; and, in women, C-reactive protein, lipoprotein(a), and glycated hemoglo

253 le (higher HDL cholesterol, lower BMI, lower C-reactive protein, lower waist circumference, and lower

254 n the absence of infection (high-sensitivity C-reactive protein <10 mg/L) and VDD as 25(OH)D <50 nmol

255 High-sensitivity C-reactive protein <2 mg/L and normal ankle-brachial ind

256 achial index >0.9 and <1.3, high-sensitivity C-reactive protein <2 mg/L, homocysteine <10 micromol/L,

257 Neither the level of C-reactive protein nor the leukocyte count at the time o

258 oidal thickness was associated with elevated C-reactive protein (odds ratio [OR]: 1.4, P = .04) and s

259 croRNAs were associated with serum levels of C-reactive protein or interleukin-6; miR-1180 was associ

260 resulted in lower levels of calprotectin and C-reactive protein (P < 0.0001), coinciding with recover

261 ike growth factor I (P = 0.002), and lowered C-reactive protein (P = 0.038).

262 ere observed for HDL cholesterol (P = 0.30), C-reactive protein (P = 0.10), PWV (P = 0.30), or AI (P

263 as higher levels of bilirubin (P=0.004) and C-reactive protein (P=0.006).

264 Male sex (P=0.048), elevated C-reactive protein (P=0.013), and carotidynia (P=0.003)

265 115 patients in the C-reactive protein point-of-care group and 72 patients i

266 We assessed whether C-reactive protein point-of-care testing can safely redu

267 nfection were assigned 1:1 to receive either C-reactive protein point-of-care testing or routine care

268 C-reactive protein point-of-care testing reduced antibio

269 1017 patients were assigned to receive C-reactive protein point-of-care testing, and 1019 patie

270 eter) and others in selected subgroups only (C-reactive protein, procalcitonin, glucometer).

271 sely with the plasma inflammation biomarkers C-reactive protein (r = -0.70, P = 0.0006), interleukin-

272 rterial inflammation (r=0.59; p=0.0345), and C-reactive protein (r=0.83; p=0.0210).

273 score, a higher number of platelets, higher C-reactive protein, regular need for pain medication, an

274 lignment increased 24-h serum interleukin-6, C-reactive protein, resistin, and tumor necrosis factor-

275 ity cardiac troponin T, and high-sensitivity C-reactive protein significantly improved global CVD and

276 re obtained: interleukin 6, high-sensitivity C-reactive protein, soluble receptors for tumor necrosis

277 (retinol-binding protein), and inflammation (C-reactive protein) status.

278 in, triglycerides, type 2 diabetes mellitus, C-reactive protein, systolic blood pressure, and type 1

279 eron gamma, tumor necrosis factor alpha, and C-reactive protein than person-visits at which 100% cART

280 such as Serum amyloid A, Apolipoprotein A1, C-reactive protein, Titin and Haptoglobin, were found to

281 renia) and metabolic (body mass index (BMI), C-reactive protein, triglycerides) traits was evaluated

282 ding neopterin, kynurenine:tryptophan ratio, C-reactive protein, tryptophan, and 6 kynurenines, as po

283 blood count, erythrocyte sedimentation rate, C-reactive protein, tuberculin skin test, syphilis serol

284 t, HIV viral load, and levels of biomarkers (C-reactive protein, tumor necrosis factor alpha [TNF-alp

285 of 2 mm/hr (normal range, 0-40 mm/hr), and a C-reactive protein value of 0.4 mg/L (3.8 nmol/L) (norma

286 median percent reduction of calprotectin and C-reactive protein was 71% for both biomarkers after ant

287 e detection of all infectious complications, C-reactive protein was also significantly more accurate

288 High-sensitivity C-reactive protein was elevated beyond the clinical cuto

289 High-sensitivity C-reactive protein was measured at baseline and at end o

290 At the fourth postoperative day, C-reactive protein was more discriminating than procalci

291 Elevated high-sensitivity C-reactive protein was more weakly associated with an in

292 High-sensitivity C-reactive protein was significantly reduced by canakinu

293 was significantly increased by 24 h, whereas C-reactive protein was unchanged.

294 pe natriuretic peptide, and high-sensitivity C-reactive protein were analyzed continuously and by est

295 ISA, soluble P-selectin, d-dimer, FVIII, and C-reactive protein were assayed.

296 operative and postoperative plasma levels of C-reactive protein were associated with delirium, sugges

297 ic peptide, tumor necrosis factor-alpha, and C-reactive protein were measured before (pretreatment) a

298 Serum levels of calprotectin and C-reactive protein were significantly higher in patients

299 ine factors such as adiponectin, leptin, and C-reactive protein which may be associated with inflamma

300 rence, triglycerides, total cholesterol, and C-reactive protein with periodontitis.